These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 795481)

  • 1. Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload.
    Nienhuis AW; Delea C; Aamodt R; Bartter F; Anderson WF
    Birth Defects Orig Artic Ser; 1976; 12(8):177-85. PubMed ID: 795481
    [No Abstract]   [Full Text] [Related]  

  • 2. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
    Cartei G; Cazzavillan M; Chisesi T; Battista R; Barbui T; Dini E
    Minerva Med; 1978 Mar; 69(13):811-21. PubMed ID: 643223
    [No Abstract]   [Full Text] [Related]  

  • 3. Desferrioxamine-induced iron outputs in Cooley's anemia. Results and perspectives.
    Cantore N; Tortarolo M; Volpe E; Gonnella F; Valente A; Buonanno G
    Haematologica; 1981 Apr; 66(2):196-207. PubMed ID: 6791996
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral ascorbic acid and iron excretion in thalassemic children treated with desferrioxamine-methansulfonate (Desferal).
    Hathirat P; Isarangkura P; Areekul S; Pleehachinda R; Tuntawiroon M
    Birth Defects Orig Artic Ser; 1988; 23(5B):129-33. PubMed ID: 3390535
    [No Abstract]   [Full Text] [Related]  

  • 5. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I; Hatzidimitriou-Papazacharia K; Spiliotopoulou J; Tsagarakis N; Digenopoulou E
    Birth Defects Orig Artic Ser; 1988; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract]   [Full Text] [Related]  

  • 6. Desferrioxamine and ascorbic acid supplement in E-B thalassaemia.
    Dutta AK; Ray R; Chandra S; Bhattacharya DK
    J Assoc Physicians India; 1988 Jul; 36(7):463-4. PubMed ID: 3204100
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic iron overload: new chelators and new strategies.
    Fairbanks VF
    J Lab Clin Med; 1978 Aug; 92(2):141-3. PubMed ID: 681806
    [No Abstract]   [Full Text] [Related]  

  • 8. [Siderinuria caused by deferoxamine. II. The siderinuric increment obtained by association with ascorbic acid].
    Cartei G; Chisesi T; Cazzavillan M; Battista R; Barbui T; Dini E
    Haematologica; 1973; 58(11):671-88. PubMed ID: 4203582
    [No Abstract]   [Full Text] [Related]  

  • 9. Iron chelation in thalassemia: mechanism of desferrioxamine action.
    Hershko C; Rachmilewitz EA
    Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis.
    Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
    Trans Assoc Am Physicians; 1977; 90():335-41. PubMed ID: 611665
    [No Abstract]   [Full Text] [Related]  

  • 11. [Changes in urinary iron in thalassemia major in relation to the administration of desferrioxamine].
    Esposito L; Ferrara M; Galdo Capotorti M
    Pediatria (Napoli); 1978 Mar; 86(1):69-76. PubMed ID: 683795
    [No Abstract]   [Full Text] [Related]  

  • 12. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
    Flynn DM; Hoffbrand AV; Politis D
    Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
    [No Abstract]   [Full Text] [Related]  

  • 13. Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies.
    Pippard MJ
    Acta Haematol; 1987; 78(2-3):206-11. PubMed ID: 3120473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ascorbic acid and iron levels in plasma and liver of vitamin C deficient guinea pigs after iron overload and desferrioxamine administration.
    Odumosu A
    Acta Vitaminol Enzymol; 1982; 4(4):299-302. PubMed ID: 7158590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical management of beta-thalassemia.
    Graziano J; Piomelli S
    Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
    [No Abstract]   [Full Text] [Related]  

  • 16. Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major.
    O'Brien RT
    Ann N Y Acad Sci; 1974; 232(0):221-5. PubMed ID: 4528431
    [No Abstract]   [Full Text] [Related]  

  • 17. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M; Galdo Capotorti M; Ponte G; Esposito L
    Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400
    [No Abstract]   [Full Text] [Related]  

  • 18. Iron absorption in iron-loading anaemias: Effect of subcutaneous desferrioxamine infusions.
    Pippard MJ; Callender ST; Warner GT; Weatherall DJ
    Lancet; 1977 Oct; 2(8041):737-9. PubMed ID: 71542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ascorbic acid on desferrioxamine therapy.
    Cartei G; Meani A
    Acta Vitaminol Enzymol; 1970; 24(6):209-13. PubMed ID: 5537933
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effects of ascorbic acid on desferrioxamine-induced siderinuria].
    Bosello O; Mengoli C; Rossi G
    Fracastoro; 1971; 64(5):310-9. PubMed ID: 5151104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.